Display options
Share it on

J Clin Immunol. 1988 May;8(3):163-70. doi: 10.1007/BF00917562.

Recognition by a human alloreactive T-cell clone of an HLA-DP-associated epitope on monocytes and fibroblasts but not on B cells.

Journal of clinical immunology

D T Umetsu, H H Jabara, P Hauschka, R S Geha

Affiliations

  1. Division of Allergy and Immunology, Children's Hospital, Boston, MA 02115.

PMID: 2455729 DOI: 10.1007/BF00917562

Abstract

We examined the ability of a panel of allospecific (N = 9) and of TT-specific (N = 15) human inducer T-cell clones to respond to antigen presented by B cells or by monocytes. With one exception all T-cell clones responded equally well to antigen presented by monocytes, by lightly irradiated (1000 rads) peripheral blood resting B cells, or by heavily irradiated (7500 rads) Epstein-Barr virus (EBV)-transformed B cells. One alloreactive human T-cell clone, Clone A1, which recognized an HLA-DP-associated antigen proliferated in response to allogeneic monocytes and gamma-interferon-treated fibroblasts but not in response to allogeneic B cells even in the presence of autologous monocytes. Nonspecific conjugate formation between B cells and Clone A1 was normal. Yet in contrast to allogeneic monocytes, allogeneic B cells failed to induce a rise in the intracellular calcium ion concentration and failed to cause interleukin 2 (IL2) receptor expression in Clone A1. Neither interleukin 1 (IL1) nor phorbol myristate acetate (PMA) reversed the inability of Clone A1 to proliferate to allogeneic B cells. The failure of allogeneic B cells to stimulate A1 was not due to their lack of expression of the HLA-DP gene product recognized by Clone A1 or to excessive sialation of this product. These results suggest that Clone A1 recognizes an epitope associated with HLA-DP which is expressed on monocytes and on gamma-interferon-treated fibroblasts but which is either absent or altered on B cells.

Similar articles

References

  1. J Immunol. 1986 Jan;136(2):446-51 - PubMed
  2. Proc Natl Acad Sci U S A. 1984 Aug;81(15):4917-21 - PubMed
  3. Nature. 1985 Dec 12-18;318(6046):558-61 - PubMed
  4. Science. 1986 Apr 18;232(4748):403-5 - PubMed
  5. Immunol Rev. 1982;64:137-60 - PubMed
  6. J Immunol. 1985 Jul;135(1):111-6 - PubMed
  7. J Exp Med. 1985 Jul 1;162(1):202-14 - PubMed
  8. J Immunol. 1985 Oct;135(4):2249-55 - PubMed
  9. J Clin Invest. 1985 Jul;76(1):254-60 - PubMed
  10. J Exp Med. 1984 Mar 1;159(3):881-905 - PubMed
  11. Immunol Rev. 1980;53:203-32 - PubMed
  12. Nature. 1984 Nov 22-28;312(5992):315-21 - PubMed
  13. Nature. 1985 Aug 8-14;316(6028):545-7 - PubMed
  14. J Immunol. 1982 Oct;129(4):1446-50 - PubMed
  15. J Exp Med. 1985 Apr 1;161(4):641-56 - PubMed
  16. Nature. 1983 Jul 28-Aug 3;304(5924):358-61 - PubMed
  17. Proc Natl Acad Sci U S A. 1983 Oct;80(19):6000-4 - PubMed
  18. J Biol Chem. 1985 Mar 25;260(6):3440-50 - PubMed
  19. Proc Natl Acad Sci U S A. 1982 Mar;79(6):1989-93 - PubMed
  20. Nature. 1984 Jan 19-25;307(5948):273-6 - PubMed
  21. J Immunol. 1985 Nov;135(5):2937-45 - PubMed
  22. J Immunol. 1985 Apr;134(4):2269-75 - PubMed
  23. J Immunol. 1978 Nov;121(5):2005-13 - PubMed
  24. J Exp Med. 1980 Dec 1;152(6):1817-22 - PubMed
  25. Nature. 1986 Sep 18-24;323(6085):262-4 - PubMed
  26. J Biol Chem. 1982 Sep 25;257(18):10766-9 - PubMed
  27. J Immunol. 1986 Jun 1;136(11):4106-12 - PubMed
  28. Nature. 1985 Jun 20-26;315(6021):641-7 - PubMed
  29. Eur J Immunol. 1985 Apr;15(4):356-61 - PubMed
  30. Nature. 1984 Dec 13-19;312(5995):639-41 - PubMed
  31. Immunol Rev. 1982;66:57-77 - PubMed
  32. J Exp Med. 1980 Oct 1;152(4):1070-84 - PubMed
  33. J Exp Med. 1982 Feb 1;155(2):445-59 - PubMed
  34. Nature. 1982 Jan 7;295(5844):68-71 - PubMed
  35. J Immunol. 1982 Apr;128(4):1764-8 - PubMed

Substances

MeSH terms

Publication Types

Grant support

LinkOut - more resources